Amylyx Pharmaceuticals Voluntarily Withdraws ALS Drug
'Relyvrio' is a prescription medicine used to treat adults with ALS. As of Thursday, it will no longer be available for new patients.
Amylyx Pharmaceuticals announced it has started the process of voluntarily pulling its ALS drug from the market.
‘Relyvrio’ is a prescription medicine used to treat adults with ALS. As of Thursday, it will no longer be available for new patients.
Those who are currently on therapy who, in consultation with their physician, wish to stay on treatment can transition to a free drug program. However, Relyvrio will no longer be prescribed after it failed a large phase in its clinical trial.
The drug reportedly did not outperform a placebo in improving participants’ ALS function scale. It also failed to significantly improve patient-reported quality of life, overall survival and respiratory function.
The company said it will continue to evaluate and share findings from the clinical trial to help inform future ALSÂ research.
